Condition
HER2-positive Carcinoma
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Margetuximab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT03133988Unknown
Margetuximab Expanded Access Program
NCT03109977Phase 1CompletedPrimary
Imaging With a New Agent That Finds a Cancer Protein Called HER2
Showing all 2 trials
Research Network
Common Treatments
- Margetuximab1
- Zrdfopertuzumab Petct1
Active Sponsors
- TerSera Therapeutics LLC1
- Memorial Sloan Kettering Cancer Center1
Top Investigators
Memorial Sloan Kettering Cancer Center
Related Conditions
- Her2positive Primary Malignancy1
- Her2positive Breast Cancer1